Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 15/20 | 0.53 |
| ▸ | JAK2 | O60674 | 14/20 | 0.53 |
| ▸ | JAK1 | P23458 | 14/20 | 0.53 |
| ▸ | SYK | P43405 | 5/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1370108 | 0.91 | JAK3 (0.53) | JAK3JAK2JAK1SYKCYP2C9 | |
| SCHEMBL1370063 | 0.90 | JAK2 (0.56) | JAK3JAK2JAK1SYKCYP2C9 | |
| SCHEMBL1368498 | 0.90 | JAK2 (0.61) | JAK3JAK2JAK1SYKCYP2C9 | |
| SCHEMBL1369095 | 0.89 | JAK3 (0.55) | JAK3JAK2JAK1SYKCYP2C9 | |
| SCHEMBL1368600 | 0.87 | JAK3 (0.58) | JAK3JAK2JAK1SYKCYP2C9 | |
| SCHEMBL1369100 | 0.86 | JAK2 (0.57) | JAK3JAK2JAK1SYKCYP2C9 | |
| SCHEMBL1369763 | 0.86 | JAK2 (0.52) | JAK3JAK2JAK1SYKCYP2C9 | |
| SCHEMBL1370798 | 0.86 | JAK3 (0.52) | JAK3JAK2JAK1SYKCYP2C9 | |
| SCHEMBL1368871 | 0.86 | SYK (0.56) | JAK3JAK2JAK1SYKCYP2C9 | |
| SCHEMBL1369466 | 0.85 | JAK2 (0.51) | JAK3JAK2JAK1SYKCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288067-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, JAK2 | JAK3 7/4885JAK2 3/4885JAK1 5/4885 |
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK2 | JAK3 7/4885JAK2 3/4885JAK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.